The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP)

Sponsor

Second Affiliated Hospital of Soochow University (Other)

Overall Status

Unknown status

CT.gov ID

NCT02854722

Collaborator

(none)

Enrollment

Location

Arms

Anticipated Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In 2006, Weinberg proposed a hypothesis that iron accumulation was a risk factor for osteoporosis. Osteoporosis is a common complication in various diseases, such as hemochromatosis, African hemosiderosis, thalassemia, and sickle cell disease, which all share iron accumulation as a common denominator. Moreover, a 3-year retrospective longitudinal study has shown that iron accumulation was also associated with osteoporosis in healthy adults and especially that it can increase the risk of fractures in postmenopausal women. Based on these observations, iron chelation therapy may have a promising future in the treatment of iron accumulation-related osteoporosis by removing iron from the body.

The purpose of this study is to determine whether the addition of the iron chelator, deferasirox, to standard therapy for postmenopausal osteoporosis, is safe and effective.

Condition or Disease	Intervention/Treatment	Phase
Postmenopausal Osteoporosis	Drug: Deferasirox and calcium-vitamin D3 Drug: Calcium-vitamin D3	Phase 2

Detailed Description

Postmenopausal osteoporosis (PMOP) is a systemic bone metabolism disease, characterized by progressive bone loss following menopause and a subsequent increase in fracture risk. Estrogen deficiency as a result of menopause is known to increase bone resorption and accelerate bone loss. Furthermore, postmenopausal women may exhibit iron accumulation, in addition to estrogen deficiency. Elevated iron levels are a risk factor for PMOP in postmenopausal women, and reducing the iron overload by iron chelators has been demonstrated to benefit bone cell metabolism in vitro and improve the bone in vivo by normalizing osteoclastic bone resorption and formation.

Although the safety and efficacy of deferasirox have been evaluated in iron-overloaded patients extensively, there are no data in iron-accumulated postmenopausal women, let alone in iron-accumulated postmenopausal women with osteoporosis. Therefore, at the currently planned dose, confirming safety and efficacy is essential in the current study to lay the groundwork for a future phase III clinical trial.

This is a prospective, phase II, randomized, open label, placebo-controlled study of calcium-vitamin D3 plus deferasirox vs. calcium-vitamin D3 for postmenopausal osteoporosis. Ten postmenopausal women diagnosed with osteoporosis by DXA, who were accompanied by iron accumulation (serum 500ng/ml≤ferritin≤1000ng/ml), will be randomized to receive calcium-vitamin D3 plus deferasirox or calcium-vitamin D3 (n = 5 per arm).

The primary objective is to determine the safety and tolerability of adjunctive deferasirox therapy in postmenopausal women being treated with calcium-vitamin D3 for osteoporosis, and to obtain exploratory data on the efficacy of the iron chelation treatment. The reduction in iron levels with deferasirox may provide a viable therapeutic option for mitigating the iron accumulation associated with PMOP.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

10 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase 2 Study of Deferasirox-calcium-vitamin D3 to Treat Postmenopausal Osteoporosis (PMOP)

Actual Study Start Date :

Jan 15, 2018

Anticipated Primary Completion Date :

Jun 15, 2019

Anticipated Study Completion Date :

Jun 15, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month. Calcium 500 mg and Vitamin D3 800 IU should also be taken daily as a basic therapy.	Drug: Deferasirox and calcium-vitamin D3 deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month. Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy. Drug: Calcium-vitamin D3 Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
Placebo Comparator: Calcium-vitamin D3 Calcium 500 mg and Vitamin D3 800 IU are taken daily as a basic therapy.	Drug: Calcium-vitamin D3 Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.

Arm

Intervention/Treatment

Experimental: Deferasirox and calcium-vitamin D3

Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month. Calcium 500 mg and Vitamin D3 800 IU should also be taken daily as a basic therapy.

Drug: Deferasirox and calcium-vitamin D3

deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month. Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy.

Drug: Calcium-vitamin D3

Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.

Placebo Comparator: Calcium-vitamin D3

Calcium 500 mg and Vitamin D3 800 IU are taken daily as a basic therapy.

Drug: Calcium-vitamin D3

Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.

Outcome Measures

Primary Outcome Measures

Number of participants with adverse events [12 months]
An adverse event was any untoward medical occurrence in participants, and did not necessarily need to have a causal relationship with the drug in the trial. The relationship of each adverse event to study drug or the severity of each adverse event was judged by the investigator, as described below. A serious adverse event is an adverse event occurring at any dose that resulted in any of the following outcomes or actions: fatal or life-threatening; requires inpatient hospitalization; persistent or significant disability/incapacity;
Number of participants with abnormal blood pressure, heart rate, body temperature, and/or physical examination that are related to the treatment [12 months]
Bone mineral density [Baseline, Month 6, Month 12]
Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. Percent changes in DXA Bone Mineral Density from baseline to month 6 and month 12 of the trial in all patients. Percent change from Baseline was calculated as (BMD at Month 6 or Month 12 - BMD at Baseline)/BMD at Baseline * 100%.

Secondary Outcome Measures

Change from baseline in serum C-terminal telopeptide of type I collagen (β-CTX) [Baseline, Month 3, Month 6, Month 9 and Month 12]
Change from baseline in serum N-aminoterminal prepeptide of type I procollagen (P1NP) [Baseline, Month 3, Month 6, Month 9 and Month 12]
Change from baseline in serum ferritin [Baseline, Month 3, Month 6, Month 9 and Month 12]
Change from baseline in blood chemistry [Baseline, Week 2, Week 4 and Month 3, Month 6, Month 9, Month 12 of the trial]
Change from baseline in hematology [Baseline, Week 2, Week 4 and Month 3, Month 6, Month 9, Month 12 of the trial]

Eligibility Criteria

Criteria

Ages Eligible for Study:

60 Years to 80 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Lumbar spine or hip BMD T-score ≤-2.5 SD.
Elevated serum ferritin (females: serum 500ng/ml≤ferritin≤1000ng/ml).

Exclusion Criteria:

Anemia < 10 g/dl
Serum liver enzymes or bilirubin above the upper limit of normal at screening.
Patients with creatinine clearance <60 ml/min will be excluded.
Known allergy or contraindication to the administration of Deferasirox.
History of blood transfusion during the 6 months prior to study entry.
Oral iron supplementation within the last 4 weeks of study entry.
Treatment with phlebotomy within 2 weeks of screening visit.
Patient is already taking deferasirox therapy for any reason at the time of screening.
Patients currently or previously treated with deferiprone or Deferasirox.
Patients with active inflammatory diseases that may interfere with the accurate measurement of serum ferritin.
Patients with a diagnosis of a clinically relevant cataract or a previous history of clinically relevant ocular toxicity related to iron chelation.